Meyer B C, Raman R, Rao R, Fellman R D, Beer J, Werner J, Zivin J A, Lyden P D
Department of Neurosciences, UCSD School of Medicine, San Diego, CA 92103-8466, USA.
Int J Stroke. 2007 Nov;2(4):281-7. doi: 10.1111/j.1747-4949.2007.00153.x.
To describe the clinical trial methods of a site-independent telemedicine system used in stroke.
A lack of readily available stroke expertise may partly explain the low rate of rt-PA use in acute stroke. Although telemedicine systems can reliably augment expertise available to rural settings, and may increase rt-PA use, point-to-point systems do require fixed base stations. Site-independent systems may minimize delay. The STRokE DOC trial assesses whether site-independent telemedicine effectively and efficiently brings rt-PA to a remote population.
STRokE DOC is a 5-year, 400-participant, noninvasive trial, comparing two consultative techniques at four remote sites. Participants are randomized to acute 'STRokE DOC telemedicine' or 'telephone' consultations. Treatment decision accuracy is adjudicated at two time points, using three levels of data availability and an independent auditor.
The primary outcome measure is whether there was a 'correct decision to treat or not to treat using rt-PA' at each of three adjudication levels (primarily at Level #2). Secondary outcomes include the number of thrombolytic recommendations, intracerebral hemorrhage, and 90-day outcomes. Using the STRokE DOC system (or telephone evaluation), medical history, neurologic scales, CT interpretations, and recommendations have been completed on over 200 participants to date. Of the initial 11, nonrandomized, 'run-in' patients, six (65%) were evaluated wirelessly, and five (45%) were evaluated with a site-independent LAN or cable modem. Three (27%) received rt-PA. The adjudication methodology was able to show both agreements and disagreements in these 11 cases. It is feasible to perform site-independent stroke consultations, and adjudicate those cases, using the STRokE DOC system and trial design. Telemedicine efficacy remains to be proven.
描述用于中风治疗的非站点依赖型远程医疗系统的临床试验方法。
缺乏随时可用的中风治疗专业知识可能部分解释了急性中风患者使用重组组织型纤溶酶原激活剂(rt-PA)的比例较低的原因。尽管远程医疗系统可以可靠地增强农村地区可用的专业知识,并可能增加rt-PA的使用,但点对点系统确实需要固定基站。非站点依赖型系统可能会将延迟降至最低。中风远程医疗文件(STRokE DOC)试验评估非站点依赖型远程医疗是否能有效且高效地为偏远地区人群提供rt-PA治疗。
STRokE DOC是一项为期5年、有400名参与者的非侵入性试验,在四个偏远地点比较两种咨询技术。参与者被随机分配接受急性“STRokE DOC远程医疗”或“电话”咨询。使用三个数据可用性级别和一名独立审核员,在两个时间点对治疗决策的准确性进行判定。
主要结局指标是在三个判定级别中的每一级(主要是在第2级)是否做出了“使用rt-PA治疗或不治疗的正确决策”。次要结局包括溶栓建议的数量、脑出血和90天的结局。使用STRokE DOC系统(或电话评估),到目前为止,已经完成了对200多名参与者的病史、神经学量表、CT解读和建议。在最初的11名非随机“预试验”患者中,6名(65%)通过无线方式进行了评估,5名(45%)通过非站点依赖型局域网或电缆调制解调器进行了评估。3名(27%)接受了rt-PA治疗。判定方法能够显示这11例病例中的一致性和不一致性。使用STRokE DOC系统和试验设计进行非站点依赖型中风咨询并对这些病例进行判定是可行的。远程医疗的疗效仍有待证实。